2024 AVBCC Annual Summit

Panels:

Building Better Alignment between Cancer Care Providers and Primary Care Groups 

ECG's Elizabeth Liebow with Michael Kolodziej, Brad Diephuis, Scott Belsky, and Alti Rahman will explore how enhanced collaboration between risk-bearing primary care groups and oncology groups can move the needle on cost and outcomes and enable mutual success in value-based care.

Efforts are underway to build better alignment between cancer care providers and risk-bearing primary care groups to further value-based care efforts. There has been a steady increase in primary care groups who are choosing to assume risk on the total cost of care for their patients, either by taking risk from MA plans or through CMS programs such as ACO REACH. However, while these organizations manage the cost of care for their entire population, they often don’t have programs or expertise in place to effectively manage the complex needs of their patients with cancer. 

Elizabeth Liebow, Principal
ECG Management Consultants

Michael Kolodziej, MD, Chief Medical Officer
Canopy

Brad Diephuis, MD, MBA, Chief Business Officer
Thyme Care

Scott Belsky, SVP Population Health
Oak Street Health

Alti Rahman, MHA, MBA, CSSBB, Chief Strategy and Innovation Officer
American Oncology Network, LLC (AON)

Oncology at Home: How Does This Option Fit into the Treatment Paradigm 

ECG's Elizabeth Liebow with Steven Peskin, Pallav Mehta, Barry Russo, Harlan Levine, and Pete Scruggs will explore the cost-effective and patient-centered alternative to hospital treatment.

Elizabeth Liebow, Principal
ECG Management Consultants

Steven Peskin, MD, MBA, MACP, Associate Clinical Professor
Robert Wood Johnson School of Medicine

Pallav Mehta, MD, Medical Director
Reimagine Care

Barry Russo, MBA, CEO
The Center for Cancer and Blood Disorders

Harlan Levine, MD, President
Health Innovation and Policy, City of Hope

Pete Scruggs, Founder
benefitSMART

Navigating the 340B Program Amidst Policy Shifts 

ECG's James Donohue with Sherri Faber, Ted Slafsky, Shannon Burger, Mark Ogunsusi, and Mesfin Tegenu will explore the profound impact on patients, the implications for various stakeholders, and will make bold predictions on the outcomes of ongoing and future decisions.  

The 340B program is at the center of a fierce debate, drawing unprecedented attention from policymakers in Washington, D.C., and across the states. Drug manufacturers are aggressively restricting access to discounts in the contract pharmacy setting, while the federal government and a growing number of states are pushing back. This politically charged program raises contentious issues with some opponents alleging abuse by large health systems, lack of transparency in savings and use by undocumented immigrants. Proponents argue that 340B is a lifeline for providers serving vulnerable patients, providing essential medications and other services at reduced costs. With Congress proposing new legislation and states leading the charge against restrictive measures, the battle lines are drawn. Multiple lawsuits by pharmaceutical companies are unfolding, and the new Medicare drug program looms large, which could have a significant impact on the program.

James Donohue, Partner
ECG Management Consultants

Sherri Faber, RPh, MHA, President & CEO
340B Compliance Partners

Ted Slafsky, MPP, Publisher & CEO
340B Report

Shannon Burger, MBA, CPA, CEO
Cempa Community Care

Mark Ogunsusi, Esq., PharmD, JD, Associate
Powers Pyles Sutter & Verville PC

Mesfin Tegenu, CEO
RxParadigm

____________________________________________________________